Biodesix Stock
Biodesix, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Country
- United States
- CEO
- Scott Hutton
- Employees
- 334
- Market cap
- $193 M
- IPO
- 28/10/2020
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate…
Biodesix stock: price history
1D
-4.2%
1W
-9.1%
1M
-17.2%
6M
+80.1%
YTD
+247.9%
1Y
+240.4%
2Y
-28.7%
5Y
-84.2%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~51% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Biodesix
Analyst assessment of Biodesix
PRICE TARGET LOW
US$32.00
CONSENSUS
US$35.00
MEDIAN
US$35.00
PRICE TARGET HIGH
US$38.00
0
STRONG BUY
8
BUY
1
HOLD
0
SELL
0
STRONG SELL
9
TOTAL · Buy
As of: 13/10/2026
Biodesix stock metrics
P/E
-7.46
P/B
26.64
EV/EBITDA
-16.39
RETURN ON EQUITY
-79.5%
NET MARGIN
-27.1%
DEBT/EQUITY
7.85
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
57.2%
FLOAT SHARES
4,656,910
AVG. DAILY VOLUME (30D)
90,662
Insider transactions (SEC)
PATIENCE JOHN
SCHULER JACK W
SCHULER JACK W
SCHULER JACK W
PATIENCE JOHN
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Biodesix stock
What does Biodesix do?
Biodesix, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Scott Hutton, the company employs around 334 people.
The IPO was on 28/10/2020; the stock trades on NASDAQ under the ticker BDSX.
What do analysts say about Biodesix stock?
9 analysts rate the stock, the consensus is Buy (as of 13/10/2026).
The average price target is US$35.00, ranging from US$32.00 to US$38.00, with a median of US$35.00.
This is an external assessment, not a statement by Market Jury.
When does Biodesix report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 51% stronger than usual.
Does Biodesix pay a dividend?
No, Biodesix currently does not pay a dividend.
Which stocks are comparable to Biodesix?
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
How can I get Biodesix stock analyzed?
Clicking "Analyze stock" lets five strategies assess Biodesix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.